• Rocket Pharmaceuticals outlined an FDA-aligned pivotal Phase 2 path for RP-A501 in Danon disease during an Oct. 6 investor webinar.
• Results were already presented, citing durable signs of benefit in Phase 1 follow-up without detailing measurements.
• Early safety observations from the first three patients on a revised dosing protocol showed no initial signs of key prior risks.
• The pivotal study targets accelerated approval, with dosing expected to finish by mid-2027, followed by topline results in mid-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007068126) on October 07, 2026, and is solely responsible for the information contained therein.